ArticleFrontiers in oncology2022

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.

Min Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.